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Gammaherpesviruses (γHV) are important pathogens causing persistent infections which
lead to several malignancies in immunocompromised patients. Murine γHV 68 (MHV-68),
a homolog to human EBV and KSHV, has been employed as a classical pathogen
to investigate the molecular pathogenicity of γHV infections. γHV express distinct
antigens during lytic or latent infection and antigen-specific T cells have a significant
role in controlling the acute and latent viral infection, although the quality of anti-viral
T cell responses required for protective immunity is not well-understood. We have
generated recombinant modified vaccinia virus Ankara (recMVA) vaccines via MVA-BAC
homologous recombination technology expressing MHV-68 ORF6 and ORF61 antigens
encoding both MHC class I and II-restricted epitopes. After vaccination, we examined
T cell responses before and after MHV-68 infection to determine their involvement in
latent virus control. We show recognition of recMVA- and MHV-68-infected APC by
ORF6 and ORF61 epitope-specific T cell lines in vitro. The recMVA vaccines efficiently
induced MHV-68-specific CD8+ and CD4+ T cell responses after a single immunization
and more pronounced after homologous prime/boost vaccination in mice. Moreover, we
exhibit protective capacity of prophylactic recMVA vaccination during early latency at day
17 after intranasal challenge with MHV-68, but failed to protect from latency at day 45.
Further T cell analysis indicated that T cell exhaustion was not responsible for the lack of
protection by recMVA vaccination in long-term latency at day 45. The data support further
efforts aiming at improved vaccine development against γHV infections with special focus
on targeting protective CD4+ T cell responses.
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INTRODUCTION
Gammaherpesvirus (γHV) infections are life-long and are associated with several oncological and
lymphoproliferative disorders particularly after immune suppression in the host (1–3). Severe
diseases in humans like Burkitt’s lymphoma, Hodgkin’s disease, or nasopharyngeal carcinoma
are known to be caused by Epstein-Barr virus (EBV). Kaposi’s sarcoma, multicentric Castleman’s
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disease or primary effusion lymphoma are related to Kaposi’s
sarcoma associated herpesvirus (KSHV) (4–9). Primarily, γHV
infection of the mucosal epithelium of the naive host is typically
asymptomatic. A subsequent productive lytic replication phase
allows the formation of latency reservoirs in B cells, dendritic cells
and macrophages (10–12). In a suppressed immune system like
in AIDS and transplant patients, the reactivation of latent γHV
leads to replication followed by disease. However, human γHV
are host-specific, therefore studies on vaccine development and
strategies against human γHV infection are limited.
Murine γHV 68 (MHV-68) is a natural rodent pathogen that
has extensive pathological similarities with and is genetically
homologous to human γHV as EBV or KSHV (13, 14). Currently
a surrogate model MHV-68 is engaged to understand the
pathogenicity of γHV and to examine the efficacy of vaccination
strategies. To date several vaccines including attenuated MHV-
68, peptide-pulsed DCs, subunit or recombinant DNA vaccines
targeting lytic and/or latent viral antigens have shown reduction
of acute infections in lungs but were unsuccessful to affect the
establishment of latent infection and host vulnerability to viral
tumorigenesis (15–22).
Notably, T cells specific for a wide range of epitopes are
fundamental to control MHV-68 infection and display two
kinetic pattern for acute or latent MHV-68 infection (23). After
mucosal infection, CD8+ T cells diminish the load of infectious
virus in lungs, while the primary lytic replication seems to
have less impact on the latent viral reservoir (24–26). Since
MHC class-II positive B cells represent the major latent virus
reservoir, cytotoxic CD4+ T cells play a significant role in
controlling γHV infection (27). Interestingly, MHV-68 ORF6
(single-stranded DNA binding protein) and ORF61 antigens
(ribonucleotide-reductase large subunit protein) are known to
stimulate both CD8+ and CD4+ T cells in C57BL/6 mice.
ORF6487 epitope-specific CD8+ T cells predominantly control
early infection while ORF61524 epitope-specific CD8+ T cells
expand in early latency and circulate at high levels throughout
the latent infection period (28–30). Moreover, control of MHV-
68 infection is provided by CD4+ T cells specific for ORF6593,
ORF61343, and ORF61691 epitopes (31).
Modified vaccinia virus Ankara (MVA) is an attenuated
strain of vaccinia virus. Due to the strong clinical safety record
MVA has been utilized as a viral vaccine vector targeting
recombinant antigens in order to induce T cell responses in
immunotherapeutic approaches against cancer and infectious
diseases (32–34). We generated recombinant MVA (recMVA)
vaccines stably expressing full length MHV-68 ORF6 and ORF61
genes. We choose en passant recombineering for insertion of
the transgene expression cassette into a self-excisable bacterial
artificial chromosome (BAC) containing the MVA genome and
allowing for the removal of the selection marker in bacteria
(35, 36). Following the rescue of infectious MVA from the self-
excisable MVA-BAC, the BAC cassette is efficiently removed
from the viral genome resulting in markerless infectious virus
progeny. To date, vector vaccine strategies based on recombinant
target gene expression were able to control lytic but not latent
MHV-68 infection proficiently. Our data show that MVA-based
vaccines expressing MHV-68 antigens ORF6 and ORF61 were
immunogenic and induced strong CD8+ and CD4+ T cell
responses. MVA-ORF6 and MVA-ORF61 proved to be effective
in a prophylactic MHV-68 challenge model and were able to
protect from MHV-68 early latency by significantly reducing
the latent virus reservoir. However, the homologous prime/boost
approach failed to protect from latency during the later course of
infection despite the presence of antigen-specific CD8+ T cells in
high frequencies.
MATERIALS AND METHODS
Cell Lines and Viruses
DF-1 (ATCC CRL 12203), HeLa (ATCC CCL-2), NIH3T3 cells
(ATCC CRL 1658), EL4 cells (ATCC TIB-39), and DC2.4 cells
(a kind gift of Kenneth L. Rock, University of Massachusetts,
USA) were grown in RPMI 1640 supplemented with 10%
fetal calf serum (FCS), 100 U/mL penicillin/streptomycin.
BHK-21 (ATCC CCL-10) cells were grown in RPMI 1640
supplemented with 5% FCS, 5% tryptose phosphate broth,
100 U/mL penicillin/streptomycin. For bone marrow-derived
dendritic cells (BMDCs), bone marrow was collected from tibiae
and femurs of C57BL/6 mice. Cells were grown in RPMI 1640
containing 10% FCS, 100 U/mL penicillin/streptomycin and 10%
granulocyte-macrophage colony-stimulating factor (GM-CSF)
described as previously (37). Working stocks of MHV-68 were
prepared by infection of BHK-21 cells as described previously
(38). MVA (cloned isolate F6) at 582nd passage on chicken
embryo fibroblasts (CEF) was routinely propagated and titered
following standard methodology (39).
Peptides
MHV-68 specific (ORF6487−495, ORF61524−531, ORF6593−607,
ORF61343−357, ORF61691−705) and control peptides
(OVA265−280, B546−60, βgal96−103, and B820) were produced
by peptides & elephants GmbH (Hennigsdorf, Germany).
Peptides were dissolved in dimethyl sulfoxide (DMSO) at a stock
concentration of 1 µg/µl.
Plasmid Construction
In order to generate MVA transfer plasmids encoding ORF6 or
ORF61 MHV-68 genes, respective DNA sequences were PCR
amplified by using modified primers designed to generate full
length cDNAs of ORF6 and ORF61 including a HA tag sequence
at the C-terminal end of each transgene. The cDNAs were
cloned in MVA transfer plasmid PH5-dVI-MVA by utilizing
BamHI+AflII restriction sites. The expression of both, ORF6
and ORF61, was under the control of the modified PH5-vaccinia
virus strong early and late promoter. The linearized transgene
expression cassette was excised by PacI restriction enzyme and
recombined in deletion VI region of MVA by utilizing 50
bp homologous flanking regions following a two step red-
recombination protocol in GS1783 E. coli harboring the GFP-
expressing MVA-BAC genome resulting in a recMVA-BAC as
described previously (40).
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Reconstitution of Recombinant MVA
Rescue of recMVA from BAC was done in DF-1 cells (41). After
transfection of recMVA-BAC DNA using turbofect according to
the manufacture’s protocol (Thermo scientific), rabbit fibroma
virus (RFV) (MOI 0.1) was added as helper virus to the cell
monolayer. After 72 h, viral plaques (CPE) were monitored
by GFP fluorescence. Cells were harvested and pelleted at
4,000 rpm for 10min at 4◦C. Supernatant was discarded
and cells resuspended in 1ml DMEM containing 10% FCS
followed by three times freeze-thawing and ultra sonification
for 30 s. Supernatant was stored at −80◦C. BAC cassette free
recMVAs were further identified by limiting dilution on DF-1
cells performed in a 96-well plate. Wild-type MVA-F6, MVA-
ORF6, and MVA-ORF61 viruses were propagated and titrated
by determining the 50% tissue culture infectious dose (TCID50)
in CEF- (39). All viruses were purified by two consecutive
ultracentrifugation steps through a 36% (wt/vol) sucrose cushion.
Recombinant MVAs were characterized for recombinant ORF6
and ORF61 protein synthesis by western blotting by using
monoclonal anti-HA antibody (Sigma) and for replication
capacity by in vitro low-multiplicity growth kinetics as previously
described (42). Briefly, confluent monolayers from one well of
six-well tissue culture plates were used per time point. After
virus adsorption, the inoculum was removed, cells were washed
and further incubated with fresh medium. At multiple time-
points post-infection (p.i.), infected cells were harvested and
virus was released by freeze±thawing and brief sonication. Serial
dilutions of the resulting lysates were plated on confluent CEF
monolayers grown in 96-well plates as replicates of eight. At
day 7, microscopic analysis monitoring for wells containing viral
plaques (CPE) allowed the determination of virus titers by end
point dilution as TCID50/ml.
Generation of T Cell Lines
All T cell lines were established by peptide stimulation of
splenocytes obtained from vaccinated mice and maintained by
periodical restimulation. For the generation of the CD8+ T cell
lines, C57BL/6 mice were vaccinated intraperitoneally (i.p.) once
with MVA-ORF6 and MVA-ORF61, respectively, and sacrificed
at 8 dpi. For the first round of stimulation, lipopolysacharide
(LPS)-activated B cells (LPS-blasts) were generated from
splenocytes from naive mice treated with 25µg/ml LPS and
7µg/ml dextransulfate for 3 days at 37◦C, 5% CO2, and 90%
humidity. LPS-blasts were irradiated (30Gy), pulsed with peptide
(250 ng/ml) for 30min at 37◦C and cocultivated with 7 × 106
splenocytes from MVA-ORF6 or MVA-ORF61 vaccinated mice
per well in 24-well plates with RPMI 1640 containing 10% FCS,
100 U/ml penicillin, and 100µg/ml streptomycin for 7 days. For
maintenance of T cell lines, the cultures were restimulated every
7 days according to the following scheme. Irradiated (100Gy),
peptide-pulsed (1µg/ml for 30min at 37◦C) EL4 cells were
adjusted to 1 × 106 cells/ml. Irradiated (30Gy) splenocytes from
naive mice were adjusted to 12 × 106 cells/ml. T cells were
adjusted to 5× 105 cells/ml. Finally, 0.5ml of peptide pulsed EL-
4 cells, 0.5ml of splenocytes, 0.5ml of 5% TCGF [conditioned
medium as supernatant from rat splenocytes stimulated with
5µg/ml concanavalin A; (37)] and 0.5ml CD8+ T cells were
added in one well of 24 well plate and cocultivated. In order
to generate CD4+ T cell lines, C57BL/6 mice were vaccinated
twice i.p. with recMVA in a short term prime-boost regimen
(prime day 0, boost day 5) as recently shown for CD8 + T cells
(43) and sacrificed at 6 d post boost. Spleens were processed as
described earlier (37). For maintenance, CD4+ T cell lines were
restimulated every 7 days for 20 weeks and thereafter every 14
days as described (37).
In vitro T Cell Assays (T Cell Lines)
BMDCs were infected in 6-well plates withMVA-F6 and recMVA
(MOI 5) for 15 h, and MHV-68 (MOI 10) for 48 h. Infected
BMDCs 4× 105/100 µl were incubated with 100 µl of Brefeldin-
A (1µg/ml) and co-cultured with 2 × 105/100 µl of antigen-
specific T cells in RPMI 1640 medium supplemented with 10%
FCS, 100 U/mL penicillin/streptomycin at 37◦C. For peptide-
pulsed control cells, 100 µl of peptide were used for CD8+ T
cell assays at 1ng/ml and at 1000 ng/ml peptide for CD4+ T cell
assays. Briefly, BMDCs were incubated for 30min at 37◦C in the
respective peptide solutions, washed and then resuspended in 100
µl of Brefeldin-A (1µg/ml) and co-cultured with 2 × 105/100
µl of antigen-specific T cells. Intracellular cytokine staining was
carried out after 4 h incubation with CD8+ T cells or 15 h with
CD4+ T cells as published earlier (37).
Immunization of Mice
Mouse husbandry was conducted under specific-pathogen-free
conditions according to the Federation of European Laboratory
Animal Science Associations protocols (FELASA) at the
“Zentrale Einrichtung für Tierforschung und wissenschaftliche
Tierschutzaufgaben (ZETT).” Experiments were performed in
accordance with German animal care and ethics legislation and
with the approval of the responsible animal welfare authority.
C57BL/6N (6–8 weeks old) female mice were purchased from
Janvier. Mice were vaccinated intraperitoneally (i.p) with 1× 108
IU wild type MVA-F6, MVA-ORF6, or MVA-ORF61 in 200 µl
PBS or PBS only as control. Vaccination was performed either
as prime only or in a short term prime-boost regimen with a
boost i.p. at day 5 (43). Spleens were harvested at day 8 after
prime or day 6 after prime-boost to measure T cell responses by
intracellular cytokine staining (ICS).
Ex vivo T Cell Analysis (Splenocytes)
For ex vivo CD8+ T cell analysis, spleens were removed from
vaccinated mice and homogenized with a syringe plunger over
metal grid with cell culture medium. Erythrocytes were lysed
with 3ml TAC buffer and washed. Cells were filtered by 70µm
cell strainer and counted. For a short T cell restimulation, 4 ×
106 splenocytes were further incubated with respective peptides
(1µg/ml) for 4 h for CD8+ T cells and for 15 h for CD4+ T cells
in the presence of BFA. As a control, T cells were stimulated in
a non-antigen-specific manner using anti-mouse CD3e antibody
(clone 500A2, BD Pharmingen 553238) at 1.25µg/ml for CD8+
T cells for 4 h and for CD4+ T cells for 15 h in presence of BFA.
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MHV-68 Challenge
To analyze the protective capacity of MVA-ORF6 and MVA-
ORF61, mice were prime-boost immunized i.p. with 1 × 108
IU of either recMVA in 200 µl PBS or MVA-F6 or PBS only
as controls. Four weeks after boosting, mice were anesthetized
and infected intranasally with 5 × 104 PFU of MHV-68 in 20
µl RPMI containing 5% FCS. Mice were sacrificed at day 17
or day 45 after challenge. Spleens were harvested to measure
weight and then processed for ex vivo T cell analysis (ICS) or
used for viral genomic load measurements by qPCR or virus
reactivation assays.
Intracellular Cytokine Staining (ICS)
T cell co-cultures with either infected BMDCs [see section
In vitro T Cell Assays (T Cell Lines)] or from ex vivo peptide-
stimulated splenocytes [see section Ex vivo T Cell Analysis
(Splenocytes)] were transferred into 96-well V-bottom plates.
Cells were incubated with blocking buffer [PBS having 1%
bovine serum albumin (BSA)] containing 1µg/ml ethidium
monoazide bromide (Life technologies GmbH, Germany) for
20min on ice under light exposure for live/dead discrimination.
Afterwards, ICS was performed using BD Cytofix/Cytoperm
fixation/permeabilization kit according to the manufacturer’s
protocol (BD Pharmingen, Germany). Briefly, cells were washed
twice with blocking buffer and surface stained with anti-
CD8-PB or anti-CD4-PB for 30min on ice. In addition, cells
were stained for CD62L (L-selectin) in order to discriminate
between T cells that were specifically reactivated after ex vivo
antigen restimulation (CD62L negative) and those that were not
reactivated in an antigen-specific manner (CD62L positive). Cells
were washed and permeabilized with Cytofix/Cytoperm solution
for 15min on ice. Thereafter, cells were washed, incubated with
anti-IFNγ, anti-TNFα or anti-IL-2 for 30min, washed again,
fixed with 2% paraformaldehyde (PFA) and subjected to flow
cytometry [BD FACSCanto II (BD Bio Sciences, Germany)].
Ex vivo Reactivation Assay (CPE)
To analyze the frequency of cells carrying viruses reactivating
from latency, NIH3T3 cells (104 cell/well) were seeded in 96-
well plate. Three-fold dilutions of splenocytes (starting from
1.5 × 105 cells/well) were plated onto NIH3T3 cells with 24
wells per dilution. After 7–14 days, each well was scored for
cytopathic effects (CPE) and the frequency of reactivating cells
was calculated on the basis of the Poisson distribution by
determining the number of cells at which 63.2% of wells scored
positive for CPE.
Measurement of Latent Viral Load by
Quantitative Real-Time PCR
Measurement of latent viral load in splenocytes of infected mice
was determined by quantitative real-time PCR using the ABI
7300 Real Time PCR System (Applied Biosystems, Foster City,
CA) as described previously (44). Briefly, a 70-bp region of the
MHV-68 glycoprotein B (gB) gene was amplified, and viral DNA
copy numbers were quantified. The murine ribosomal protein L8
(rpl8) was amplified in parallel and used to normalize for input
DNA between samples. The data are presented as viral genome
copy numbers relative to the copy number of L8.
Analysis of Exhaustion Markers
Mice were prime/boost immunized and challenged as described
in sections Immunization of Mice and MHV-68 Challenge,
respectively. Spleens were removed from vaccinated mice and
homogenized with a syringe plunger over metal grid with cell
culture medium. Erythrocytes were lysed with 3ml TAC buffer
and washed. Cells were filtered by 70µm cell strainer, counted
and stained with aqua dye (Invitrogen) followed by mouse anti-
CD8PB, anti-CD4 PerCP (eBioscience), anti-PD-1 FITC and
anti-CTLA-4 APC (Invitrogen) surface antibody staining as well
as anti-Eomes PECy7 and anti-T-bet PE (Invitrogen) intracellular
antibody staining as described in section Intracellular Cytokine
Staining (ICS).
Statistical Analysis
All data are shown as mean ± SEM of the number of individual
mice indicated with n either pooled from or representative for the
respective number of independent experiments. The statistical
significance was analyzed by an unpaired Student’s t-test (two-
tailed) using GraphPad Prism 6. p ≤ 0.05 were considered as
significant Manuscript Formatting.
RESULTS
Generation and in vitro Characterization of
Recombinant MVA Vaccines
Initially, we cloned cDNAs of MHV-68 ORF6 or ORF61 genes
into MVA transfer plasmid PH5_dVI_MVA. After the PacI-
restricted digestion of transfer plasmids, the linearized transgene
expression cassette was transferred into GS1783 E. coli cells
containing theMVA-BAC genome including a BAC-GFP cassette
residing in the deletion-III region (Figure 1A). The en passant
technique based on the red recombination system (40) was
applied to recombine the transgene expression cassette into
deletion VI of the MVA-BAC (36, 40, 45, 46) (Figure 1A).
Moreover, the aphAI (kanamycin) marker gene present in
the expression cassette to positively select recMVA-BAC was
removed following en passant recombination of homologous
sequences of the I-SceI homing endonuclease which flanked
the aphAI gene (Figure 1A). Furthermore, the complete BAC
expression cassette was removed by homologous recombination
after BAC rescue (self-excising BAC) in DF-1 cells (35, 41,
47). Sequencing assured the right insertion as well as correct
orientation and sequence of the recombinant expression cassette
for both recMVA. Additionally, we analyzed the target protein
synthesis by using MVA-ORF6 and MVA-ORF61 infected HeLa
cell lysates. Western blot analysis using HA-specific antibodies
able to bind the C-terminal HA-tag of the recombinant ORF6
and ORF61 proteins confirmed the expected size of ORF6
(124 kDa) and ORF61 (90 kDa), respectively (Figure 1B, blot
image spliced and grouped). Importantly, both recMVA showed
similar replication capacity in vitro as compared to wild type
MVA-F6 (Figure 1C).
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FIGURE 1 | (A) Schematic map of the MVA-BAC genome (HindIII restriction map) including the BAC-GFP cassette as well as the MVA transfer plasmid containing the
respective MHV-68 gene (either ORF6 or ORF61). Flank 1 and 2 are homologous sequences necessary to integrate into the site of deletion IV within the MVA genome.
I-SceI restriction site is next to aphAI gene, whereas DX
′′
marks homologous flanks allowing the deletion of aphAI through homologous recombination. The final
recombinant MVA with aphAI marker gene deletion is shown at the bottom. (B) Synthesis of recombinant HA-tagged ORF6 (single-stranded DNA binding protein) and
ORF61 (ribonucleotide-reductase large subunit protein) (Western blot analysis) after infection of Hela cells with MVA-ORF6, MVA-ORF61, or MVA wild type (as
negative control) (MOI-10). For positive control, HeLa cells were transfected with plasmid pIRES-eGFP encoding an HA-tagged HCMV US6 gene and infected with
MVA wild type. Cell lysates were harvested after 24 h and run through the SDS 10% PAGE. Immunobloting was done by using HA-specific monoclonal antibodies.
The image of the blot was spliced and grouped for editorial purposes. (C) Low-multiplicity growth of MVA-ORF6 and MVA-ORF61. Viruses showed similar growth
kinetics compared to MVA wild type (MVA-F6) on CEF cells infected at low MOI of 0.01. Viral titers were determined by end point dilution at indicated hours post
infection (h.p.i.) to obtain a 50% tissue culture infectious dose (TCID50).
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Primary CD8+ and CD4+ T Cell Responses
After recMVA Vaccination
ORF6- and ORF61-specific CD8+ T cells dominate the MHV-
68-directed CD8+ T cell response (25). In addition, ORF6 and
ORF61 antigens induce a substantial CD4+ T cell response
during MHV-68 infection (31). Thus, we examined the capacity
of MVA-ORF6 and MVA-ORF61 vaccines to elicit ORF6- and
ORF61-specific CD8+ and CD4+ T cells. T cell responses
were determined at day 8 after vaccination (Figure 2A) and
showed efficient priming of ORF6- and ORF61-specific CD8+
(Figures 2B,C) and CD4+ T cells (Figures 2D,E) using MVA-
ORF6 or MVA-ORF61. About 2% of ORF6487-specific and 1%
ORF61524-specific CD8+ T cells produced IFNγ and to a lesser
extend TNFα (Figures 2B,C). ORF6 and ORF61-specific primary
CD4+ T cells produced IFNγ and IL-2 after vaccination with
MVA-ORF6 or MVA-ORF61, respectively (Figures 2D,E). T-
cell responses against MHV-68 antigens accompanied those to
dominant MHC class I or II restricted vaccinia virus (VACV)
epitopes such as B820 or B546, respectively. B8 and B5 antigens
are expressed by various VACV strains including MVA and
served as infection controls and helped to validate the efficacy
of recMVA vaccination comparative to MVA-wt for CD8+ and
CD4+T cells, respectively (48). AlthoughMVA-ORF6 andMVA-
ORF61 were considered to be immunogenic and elicited ORF6-
and ORF61-specific CD4+ and CD8+ T cells, some epitope
specificities such as ORF6593-specific CD4+ T cells were of
low frequency after a single vaccination. This was particularly
obvious in the memory phase at day 35 p.i. in which CD8+ and
CD4+ T cell responses strongly contracted, yet to still detectable
levels (Supplementary Figure 1).
Ex vivo Analysis of CD8+ and CD4+ T Cell
Responses After Prime-Boost Vaccination
Next, we determined the antigen-specific T cell responses
after prime-boost immunizations with MVA-ORF6 or -ORF61.
Mice received a homologous boost vaccination at day 5
post primary immunization (Figure 3A) consistent with a
short period prime-boost vaccination protocol (43). This
protocol has been demonstrated to result in equally efficient
antigen-specific T cell expansion as compared to standard
boosting at day 30 post priming. Saving time may be
beneficial under certain circumstances in order to allow for
earlier protective immunity or to shorten costs. At day
6 post boost, MVA-ORF6 vaccination resulted in higher
levels of CD8+ IFNγ+ T cells (6%) specific for ORF6487
(Figure 3B) as compared to a single immunization (Figure 2B,
Supplementary Figure 1A). The expansion of CD8+ IFNγ+
T cells in the secondary response to MVA-ORF61 (1.5%) was
not significant (Figure 3B) compared to a single immunization
(Figure 2C, Supplementary Figure 1C). Likewise, high levels of
IFNγ producing ORF6593-, ORF61343-, or ORF61691-specific
activated CD4+ T cells (0.25–0.3%) were observed (Figure 3C).
Interestingly, ORF6593-specific responses were similar to the
primary response in the acute phase (day 8), whereas ORF61343
and ORF61691 epitope-specific responses were comparatively
reduced (Figures 2D,E). In comparison to the memory response
after single immunization, however, we could still observe a boost
effect for all epitopes tested (Supplementary Figures 1B,D). The
data indicates good capabilities of MVA-ORF6 and -ORF61
to induce antigen-specific memory T cell responses that could
reactivate and expand after boost immunization.
ORF6 and ORF61-Specific T Cell Lines
Recognize Infected BMDC in vitro
Since ORF6 and ORF61 encode both, MHC class-I- and II-
restricted epitopes, we tested the endogenous presentation of
ORF6- and ORF61-specific epitopes in recMVA or MHV-
68 infected target cells by determining the recognition by
polyclonal epitope-specific CD8+ or CD4+T cell lines generated
from recMVA-vaccinated mice. Interestingly, BMDCs infected
with MVA-ORF6, MVA-ORF61 or MHV-68 and co-cultivated
with CD8+ T cells specific for ORF6487 and ORF61524
epitopes, activated both CD8+ T cell lines as good as peptide-
pulsed BMDCs used as a positive control (Figures 4A,B).
Likewise, we investigated MHC class-II-restricted endogenous
recognition of infected BMDCs by MHV-68-specific CD4+
T cells (Figures 4C–E) (37). ORF6593-specific CD4+ T cells
were activated indicating efficient MHC class II-restricted
presentation by MVA-ORF6 or MHV-68-infected BMDCs
(Figure 4C). While MVA-ORF61-infected BMDCs activated
ORF61343- and ORF61691-specific CD4+ T cells, MHV-68-
infected BMDCs failed to stimulate both ORF61-specific
CD4+ T cell lines (Figures 4D,E). Of note, we determined
a comparable affinity for ORF6487 and ORF61524-specific
CD8+ T cells (Supplementary Figure 2A). In contrast to
ORF61-specific CD4+ T cells, ORF6593-specific CD4+ T
cells displayed higher affinity to their peptide/MHC class II
complexes (Supplementary Figure 2B).
Protection From Early Latency but Not
From Established Latency by Prophylactic
RecMVA Vaccines After MHV-68 Challenge
Following acute infection via the intranasal route, MHV-
68 scatter from lungs to secondary lymphoid organs
where persistent infection is established in latently infected
B-lymphocytes, dendritic cells and macrophages (10).
Splenomegaly is a marker for latency as a result of increased
B and T cell numbers which peaks at day 14 post infection
(24, 49). Accordingly, we determined the ability of recMVA
vaccines to protect from viral latency by quantifying the latent
viral load and the reactivation capacity of latent viruses (50).
We vaccinated mice i.p. followed by a homologous boost
vaccination at day 5. Four weeks after the boost, mice were
challenged i.n. with MHV-68 (Figure 5A). At day 17 or day 45
post challenge, corresponding to the early or established latent
phase of infection, respectively, protection was evaluated.
At day 17, MVA-ORF6- and MVA-ORF61-pre-immunized
mice showed a highly significant reduction in spleen weight
(Figure 5B) and a decrease in latent virus as quantified by the
number of reactivating splenocytes (Figure 5C) as compared
to the control groups (MVA-F6 or PBS). In MVA-F6 or PBS
immunized control groups, the frequency of splenocytes allowing
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FIGURE 2 | Primary CD8+ and CD4+ T cell response after recMVA vaccination. (A) C57BL/6 mice were vaccinated i.p. using 1 × 108 IU/200 µl of MVA-F6 (wildtype),
MVA-ORF6 or MVA-ORF61 or 200 µl of PBS as a control group. For ex vivo T cell analysis (ICS followed by FACS) splenocytes were prepared from immunized mice
at 8 dpi. (B,C) CD8+ T cell response. (B) Frequencies of activated (CD62L-) ORF6487- or (C) ORF61524 specific CD8+ T cells producing IFNγ (left panel) or TNFα
(right panel). βgal96 or B820 peptides were used as unrelated or MVA-specific controls, respectively (D,E) CD4+ T cell response. (D) Frequencies of activated
(CD62L-) ORF6593- or (E) ORF61343- and ORF61691-specific CD4+ T cells producing IFNγ (left panel) or IL2 (right panel). OVA265 or B546 peptides were used as
unrelated or MVA-specific controls, respectively. Data shown are mean ± SEM of n = 6 mice per group, pooled from 3 (B,C) or two independent experiments (D,E).
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FIGURE 3 | RecMVA prime-boost vaccination (A) Vaccination strategy. C57BL/6 mice were vaccinated i.p. with 1 × 108 IU/200 µl MVA-F6, MVA-ORF6 or
MVA-ORF61. At day 6 of post boost, splenocytes were prepapared for ex vivo T cell analysis (ICS/FACS). (B) CD8+ T cells. Frequencies of activated (CD62L-) IFNγ
producing ORF6487- and ORF61524 -specific CD8+ T cells. (C) CD4+ T cells. Frequencies of activated (CD62L−) IFNγ producing ORF6593−, ORF61343−, and
ORF61691− specific CD4+ T cells. Data shown are mean ± SEM of n = 10 mice per group, pooled from two independent experiments.
for MHV-68 reactivation from latency was 1 in 5,565 cells
and 1 in 5,964 cells, respectively. The amount of reactivating
splenocytes was 1 in 64,609 cells MVA-ORF61 and 1 in 117,065
cells for MVA-ORF6 immunized animals. Likewise compared
to the control groups, MVA-ORF6 or MVA-ORF61 vaccination
resulted in a significant decrease of the splenic latent viral
genomic load as quantified by real-time PCR (Figure 5D). These
results were corroborated by the IFNγ producing CD8+ T cell
frequencies in MVA-ORF6 or MVA-ORF61 vaccinated mice after
MHV-68 challenge which were significantly higher (Figure 6A).
Interestingly, the amount of IFNγ producing CD4+CD62L- T
cells were significantly lower in these two vaccination groups
as compared to the controls (MVA-F6 or PBS) (Figure 6B).
Since these activated IFNγ producing ORF6- and ORF61-
specific CD4+ T cells were also significantly reduced in absolute
numbers, we suggest that the decrease was not due to a shift
in the relative distribution but rather indicates the consumption
of these T cell specificities as effectors for direct killing of
virus infected cells (Supplementary Figure 3). There were no
obvious differences regarding antigen-specific TNFα production
in CD8+ T cells (Figure 6C) or IL-2 production in CD4+
T cells (Figure 6D, Supplementary Figure 3) underlining the
importance of IFNγ for protection in early latency.
Surprisingly, both vaccines failed to confer long-term
reduction in latency, since we could not detect a sustained
decrease in spleen weight (Figure 7A) and viral genomic load
(Figure 7B) at day 45 post challenge as compared to the
controls. Interestingly, the T cell analysis showed a significantly
higher IFNγ-producing CD8+ T cell response directed against
ORF6 and ORF61 as compared to control vaccinated animals
(Figure 7C), while CD4+ T cell frequencies for both, ORF6 and
ORF61, were comparable in all groups (Figure 7D). In addition,
MVA-ORF6 vaccinatedmice contained significantly more ORF6-
specific TNFα-producing CD8+ T cells compared to the other
vaccine groups (Figure 7C, lower panel) which corroborated
the data obtained for IFNγ. In contrast, ORF61-specific TNFα-
production was comparable between vaccine groups (Figure 7C,
lower panel). Interestingly, we failed to detect ORF6- or ORF61-
specific IL-2 production in all CD4+ T cells at day 45 (Figure 7D,
lower panel) which may indicate that the low CD4+ T cell
response seen in long-term latency might be due to lack of
proliferation or even exhaustion. Thus, although present in high
numbers, antigen-specific CD8+ T cells failed to control latency
at later time points.
Loss of Protection in Late Latency at Day
45 Is Not Driven by T Cell Exhaustion
As mentioned above, T cell exhaustion especially targeting
CD4+ T cells during the course of MHV-68 infection could
be a reason for the transient and timely limited protective
Frontiers in Immunology | www.frontiersin.org 8 December 2019 | Volume 10 | Article 2984
Samreen et al. MVA Vaccines Targeting Murine γ-Herpesvirus
FIGURE 4 | Antigen processing and presentation of ORF6 and ORF61 antigens. After infection with MVA-F6, MVA-ORF6 or MVA-ORF61 (MOI 5) for 15 h or with
MHV-68 (MOI 10) for 48 h, BMDCs were co-incubated with CD8+ T cells (A,B) or CD4+ T cells (C–E). CD8+ T cells specific for (A) ORF6487 or (B) ORF61524
epitopes were co-incubated for 4 h; CD4+ T cells specific for (C) ORF6593, (D) ORF61343, or (E) ORF61691 epitopes for 15 h. BMDCs pulsed with the cognate
MHC-class-I (A,B) and -II-restricted peptides (C–E) at a concentration of 1 or 1,000 ng/ml, respectively, were used as positive controls: (A) ORF6-487, (B)
ORF61−524, (C) ORF6-593, (D) ORF61−343, and (E) ORF61−691. BMDCs pulsed with irrelevant peptide (ctrl peptide) as well as uninfected or MVA-F6-infected
BMDCs served as negative or infection controls, respectively. Cytokine production [IFNγ (A–E), TNFα (A,B)] was determined by ICS and FACS analysis. Data are
mean ± SEM of n = 4 mice per group, pooled from two independent experiments.
capacity of recMVA vaccines. We therefore monitored the
CD8+ and CD4+ T cell responses at day 17 and day 45 post
challenge for the expression of characteristic markers of T cell
exhaustion such as the inhibitory receptors PD-1 and CTLA-4
as well as the transcription factors Eomes and T-bet (Figure 8).
Interestingly, the expression of exhaustion marker PD-1 was
highly significantly reduced in CD4+ and CD8+ T cells in all
groups at day 45 compared to day 17 (Figure 8A). The expression
of CTLA-4 did not change between day 45 and day 17 in
CD8+ T cells and was significantly reduced in CD4+ T cells for
all groups apart from the MVA-ORF6-vaccinated group which
showed comparable expression of CTLA-4 at days 45 and 17
(Figure 8B). In addition, PD-1/T-bet double positive cells most
likely representing early exhausted T cells as well as PD-1/Eomes
double positive cells indicating most likely terminally exhausted
T cells were significantly diminished in CD4+ as well as CD8+
T cells in all corresponding groups at day 45 compared to day17
(Figure 8C). Of note, T cell frequencies were considerably low
and close to detection limit for all markers except PD-1 at day
45. Since exhaustion markers were not increased in any of the
groups by day 45, but in contrast strongly decreased at day 45
with the exception of CTLA-4 in CD8+ T cells, we conclude that
T cell exhaustion did not contribute to the loss of protection by
recMVA vaccines in established latency at day 45.
DISCUSSION
Recombinant vaccines based on MVA expressing MHV-68
antigens have been constructed employing an MVA-BAC
recombination system based on the en passant technique which
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FIGURE 5 | Protection from MHV-68 early latency. (A) C57BL/6 mice were i.p. prime/boost vaccinated using 1 × 108 IU/200 µl MVA-ORF6, MVA-ORF61, MVA-F6
(as infection control) or PBS (as mock control). Four weeks later, mice were challenged i.n. by using 5 × 104 PFU/20 µl of MHV-68. At 17 days post challenge, (B)
spleen weights, and (C) latent viral load by ex vivo reactivation or (D) by Real Time PCR were determined. (B) Mean spleen weight ± SEM of n = 8–10 mice per
group, pooled from three independent experiments. Age-matched mice which received no treatment at all (no vaccination, no challenge) served as control littermates
(naïve, spleen weight ± SEM of n = 4). (C,D) Single splenocytes suspensions from day 17 after MHV-68 challenge were used (C) to determine the latent viral load by
ex vivo reactivation of splenocytes or (D) for isolation of DNA to measure latent viral copy load by Real Time PCR analysis. (C) Mean frequency of reactivation
replication of latent virus ± SEM from n = 6–9 mice per group, pooled from three independent experiments. The horizontal dotted line specifies the point of 63.2%
Poisson distribution, set by the non-linear regression that was used to calculate the frequency within the cells. For calculation of significance, frequencies of
reactivation events were statistically analyzed by paired t-test over all cell dilutions. The statistical difference of MVA-ORF6 immunized group to PBS is P = 0.008 and
to MVA-F6 P = 0.005. The statistical difference of MVA-ORF61 immunized group to PBS is P = 0.009 and to MVA-F6 P = 0.007. (D) Mean viral genomic load in the
spleen from n = 5–8 mice per group, pooled from two independent experiments is indicated by horizontal bars. Each symbol represents an individual mouse.
Statistical significance (P).
has been described as a comparatively fast and easy method
(35). In favor of possible vaccine application, we applied
a self-excisable MVA-BAC in which the BAC cassette was
subsequently removed from recMVA genomes by site specific
recombination (41). BAC-less MVA-ORF6 and MVA-ORF61
efficiently expressed ther recombinant target genes and displayed
standard growth kinetics in vitro.
As T cells are pivotal to control γHV infections, we monitored
the T cell response after immunization with recMVA and
investigated the efficacy of MHV-68-infected target cells to
stimulate CD8+ and CD4+ T cells in vitro, as an indication
of direct antigen processing and presentation. Nevertheless,
direct as well as cross-priming contribute to MVA-induced
CD8+ T cell responses (51–53). After a single vaccination
with MVA-ORF6 or MVA-ORF61 we observed strong but
subdominant target antigen-specific effector CD8+ T cell
responses during the acute phase of infection (8 dpi) (43, 54–
56). As expected, in the memory phase of infection CD8+ T
cell frequencies contracted to about 10% of the initial maximum
(Supplementary Figures 1A,C). ORF6 and−61 antigens were
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FIGURE 6 | CD8+ and CD4+ T cell responses in recMVA-prime/boost vaccinated mice 17 days after MHV-68 challenge. (A) Detection of activated (CD62L−) IFNγ-
or (C) TNFα-producing ORF6- and ORF61-specific CD8+ T cells (ICS followed by FACS analysis). Splenocytes were stimulated with peptide epitopes
ORF6487/ORF61524, βgal499 (negative control) or B820 (vaccination control). (B) Detection of activated (CD62L-) IFNγ- or (D) IL2-producing ORF6- and
ORF61-specific CD4+ T cells. Splenocytes were stimulated with peptide epitopes ORF6593, ORF61343-, ORF61691, OVA265 (negative control) or B546 (vaccination
control). (A–D) CD3 indicates T cell stimulation using anti-CD3 antibodies as non-antigen-specific positive control. The statistical significance was calculated using an
un-paired t-test. Data shown are mean ± SEM of n = 11 mice for each group, pooled from three independent experiments.
expressed under control of the modified PH5 early/late promoter
resulting in enhanced transgene expression (57). In addition,
both MVA-ORF6 and MVA-ORF61 vaccines induced effector
CD4+ T cell responses upon primary vaccination, but only
ORF6-specific CD4+ T cells were clearly detectable in the
memory phase (35 dpi) (Supplementary Figures 1B,D). Of note,
next to ORF61-specific memory CD4+ T cells, MVA-ORF61-
induced B546-specific memory CD4+ T cell responses were
hardly detectable as well, implicating that these CD4+ T cells
primarily differentiated into effector T cells (CD62Llow) after
immunization leaving low memory CD4+ T cell responses
(58). RecMVA has been often used as vector for boost
vaccinations (59–61) and allows for short-term prime-boost
immunization strategies (43). Likewise, our data indicate that
MVA-ORF6− and -ORF61 efficiently expanded CD4+ and
CD8+ T cells following this short-term prime-boost regimen
even at low to undetectable numbers of pre-existing memory
CD4+ T cells.
Furthermore, the endogenous processing and presentation
of viral antigens by infected target cells was analyzed by using
antigen-specific CD8+/CD4+ T cell lines which were generated
from recMVA-vaccinated mice. These effector memory-like T
cells were used as in vitro readout system (37, 43). MHV-68
ORF6 which encodes for a single-stranded DNA binding protein,
seemed to be efficiently processed and both, MHC-I- and -II
restricted epitopes, presented as ORF6-specific CD8+ and CD4+
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FIGURE 7 | Vaccination with MVA-ORF6 or MVA-ORF61 fails to protect from MHV-68 latency at day 45. C57BL/6 mice were i.p. prime/boost vaccinated using 1 ×
108 IU/200 µl MVA-ORF6, MVA-ORF61, MVA-F6 (as infection control) or PBS (as mock control). Four weeks later, mice were challenged i.n. with 5 × 104 PFU/20 µl
of MHV-68. Mice which received no treatment at all (no vaccination, no challenge) served as control littermates (naïve). At 45 days post challenge, (A) whole spleen
weights or (B) latent viral copy load by Real Time PCR of DNA isolated from single splenocyte suspensions were determined. (A) Mean spleen weight (horizontal bars)
of n = 4–8 mice per group pooled from two independent experiments. (B) Mean viral genomic load in spleen from n = 4–8 mice per group pooled from two
independent experiments as indicated by horizontal bars. (C) CD8+ and (D) CD4+ T cell responses in recMVA-prime/boost vaccinated mice 45 days after MHV-68
challenge. (C) Detection of activated (CD62L-) IFNγ- (upper panel) or TNFα-producing (lower panel) ORF6- and ORF61-specific CD8+ T cells (ICS followed by FACS
analysis). Splenocytes were stimulated with peptide epitopes ORF6487, ORF61524, or OVA257 (negative control). (D) Detection of activated (CD62L-) IFNγ- (upper
panel) or IL-2-producing (lower panel) ORF6- and ORF61-specific CD4+ T cells. Splenocytes were stimulated with peptide epitopes ORF6593, ORF61343, or OVA265
(negative control). (C,D) CD3 indicates T cell stimulation using anti-CD3 antibody as non-antigen-specific positive control. The statistical significance was calculated
using an un-paired t-test. Data shown are mean ± SEM of n = 8 mice for each group, pooled from two independent experiments. Statistical significance (P);
*P ≤ 0.05; ****P ≤ 0.0001. (A–D) Each symbol represents an individual mouse.
T cells were activated upon exposure to MVA-ORF6 or MHV-68-
infected target cells. After infection of target cells with recMVA
or MHV-68 encoding ORF61 a ribonuleotide-reductase large
subunit protein, CD8+ T cells were specifically activated, while
CD4T cells were less responsive (recMVA) or completely failed
to respond (MHV-68). Interestingly, EBV-BPLF1 is known to
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FIGURE 8 | Lack of protection by recMVA vaccines in long-term latency at day 45 post challenge is not due to T cell exhaustion. C57BL/6 mice were i.p prime/boost
vaccinated with 1 × 108 IU/200 µl MVA-ORF6, MVA-ORF61, MVA-F6 (as infection control) or PBS (as mock control). Four weeks later, mice were challenged i.n. with
5 × 104 PFU/20 µl MHV-68. On day 17 (d17) or day 45 (d45) post challenge, splenocytes were prepared and the expression of exhaustion markers such as inhibitory
receptors PD-1 (A) and CTLA-4 (B) or transcription factors such as Eomes or T-bet within PD-1-positive T cells (C) determined for CD8+ (upper panels) and CD4+ T
cells (lower panels) using specific antibodies (FACS analysis). The statistical significance was calculated using an un-paired t-test. Data shown are mean ± SEM of n =
5–6 mice for each group, pooled from two independent experiments. Statistical significance (P); *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; n.s., Non-significant.
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interact with its large subunit with ribonucleotide-reductase and
removes its ubiquitin chain, thereby decreasing the activity of
ribonucleotide-reductase in vitro, while MHV-68 ribonucleotide-
reductase has been shown to colocalize with subnuclear
structures named PML-nuclear bodies (promyelocytic leukemia
protein) (62). We propose the possibility that processing of
ORF61 as an antigen encodingMHC-II-restricted epitopes might
be decreased in vitro due to the MHV-68 deubiquitinase enzyme
(DUB) encoded by ORF64 similar as in the case of EBV.
Further studies are required to elucidate the processing of the
ORF61 antigen.
Our data indicate that recMVA vaccines induce MHV-68–
specific long-term memory T cell responses after primary as well
as boost vaccination. Previously, post exposure vaccinations with
recombinant replication-competent vaccinia viruses (VACV-
ORF6487 and VACV-Orf61524) have shown a transient viral
replication control in lungs but had no impact on latency
establishment (28). Therefore, we were interested in the
protective efficacy of recMVA on the establishment of MHV-
68 latency at early (day 17) and late time points (day 45) in a
prophylactic vaccination setting. At day 17 in early latency, the
spleen weights and splenic viral copy loads were significantly
reduced in both groups of recMVA-immunized mice. However,
in established latency at day 45, both vaccination groups were
comparable to the controls and the protective capacity was
lost. CD8+ T cells are involved in resolving splenomegaly
which is important in control of long-term latent infection,
while the manifestation of splenomegaly is driven by CD4+
T cells depending on MHV-68-infected B-cells in the spleen
(63–67). We observed that both rec-ORF6-MVA and rec-
ORF61-MVA vaccines maintained strong effector CD8+ T cell
responses for both time points tested in the latent phase of
MHV-68 infection. Those antigen specific CD8+ T cells were
able to proliferate efficiently in response to a challenge with
MHV-68 encoding the cognate epitopes. In contrast, ORF6-
and ORF61-specific effector CD4+ T cells were significantly
reduced in frequency and absolute numbers as compared to
mice without pre-existing immunity to ORF6 or ORF61 in early
latency, while they were indistinguishable from the controls
at day 45.
CD8+ T cells are not sufficient to prevent lytic or persistent
MHV-68 infection, however they contribute to CD4+ T cells
which mainly control the latent infection (67). These CD4+
T cells have effector functions which are mediated by IFNγ
production and/or cytotoxicity. Our data corroborate this view,
since rec-MVA induced strong effector CD4+ T cells producing
IFNγ which may have been consumed to control the latent
infection. MHV-68 shows persistent infection in IFNγ−/− or
IFNγ receptor−/− mice, indicating a role of IFNγ in limiting
the lytic infection or inhibiting reactivation from latent infection
(68, 69). The loss of ORF6 and ORF61 specific CD4+ T
cells in recMVA-vaccinated groups after challenge supports
this effector function and correlates with decreased spleen
weight as a marker for splenomegaly (63, 70) as well as the
reduced latent virus reservoir in these mice early at day 17.
However, these CD4+ T cells were unable to control long-
term latency and were present at comparable frequency as in
control groups, possibly because they were consumed and/or
unable to proliferate. The latter is supported by the loss of
IL-2 production in these cells at day 45 supporting the view
that particularly CD4+ T cells may be required for long-
term infection control (27, 71). T cell exhaustion as described
for some chronic infections (72) could be a reason for the
restricted protective capacity of recMVA vaccines. However, a
comparative T cell analysis for exhaustion markers such as
the inhibitory receptors PD-1 and CTLA-4 or the transcription
factors Eomes and T-bet at day 17 and day 45 excluded a role
of T cell exhaustion at day 45. The CD4+ T cell frequencies
expressing PD-1 or CTLA-4 were significantly decreased in all
corresponding groups at day 45 compared to day 17, with
the exception of the MVA-ORF6 group. Similarly, we found
a significant decrease of CD4+ and CD8+ T cell frequencies
coexpressing exaustion markers such as PD-1 and T-bet (early
exhaustion) or PD-1 and Eomes (terminal exhaustion) (72–
74) in corresponding groups at day 45 compared to day 17.
We therefore conclude that the lack of protection by recMVA
vaccines in established latency in this model was not mediated
by T cell exhaustion.
Up to now exclusively live-attenuated γHV e.g., latency-
deficient mutants were able to partially protect from latency
(18, 75–78). A more recent study demonstrated that the
protection mediated by latency-deficient mutants does not
require immunity to any of the known latency genes in MHV-
68. This suggests that lytic access to the latency reservoir
is indeed a viable target for control (79). The prime/boost
vaccination regimen based on recMVA expressing ORF6 and
ORF61 had a profound impact on the quality and quantity
of MHV-68-specific T cell responses. The vaccines proved to
be protective in early latency by limiting latent viral infection.
The failure to protect from long-term latency offers now the
chance and basis to test advanced strategies to further enhance
the CD4+ T cell response such as heterologous prime/boost
regimens by combining antibody-targeted vaccines or DNA-,
protein- or viral vector-based (e.g., Adeno, VSV) vaccines
for priming and MVA for boosting. These approaches have
been shown to significantly increase target antigen-specific
T cell responses and enhance their efficacy in preclinical
models as well as in clinical studies (80, 81). Alternatively,
direct targeting of ORF6 or-61 antigens to the MHC class
II processing pathway, e.g., by fusion to the MHC class II-
associated invariant chain Ii, may be an option. A recent
study provided evidence that combined intranasal/intramuscular
vaccination of mice using a heterologous adenovirus-based
prime/boost protocol reduced the risk of latency establishment
after intranasal MHV-68 challenge. Interestingly, exclusively
CD8+ T cells were targeted by the polytope vaccine and it
was hypothesized that their redirection to the mucosal viral
entry site abrogated the infection before latency was established
(82). Alternatively, tissue-resident memory cells may have been
induced and efficiently controlled the initial viral challenge load
at the mucosa. The recMVA evaluated here seem promising
model candidates to test immunotherapeutic approaches for
long-term latent virus control even in immunocompromised
hosts, e.g., by simultaneous vaccination with both constructs
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or in combination with adoptive transfer of antigen-specific
T cells. Our findings have important implication for the use
and the future design of vaccine based immunotherapy against
gammaherpesvirus infections.
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